Emergent BioSolutions, Inc. (EBS)
12.63
+0.09
(+0.72%)
USD |
NYSE |
Dec 24, 16:00
Emergent BioSolutions Cash from Investing (Quarterly): -3.40M for Sept. 30, 2025
Cash from Investing (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| Black Diamond Therapeutics, Inc. | 8.59M |
| NovaBay Pharmaceuticals, Inc. | 0.00 |
| Palatin Technologies, Inc. | 0.00 |
| Theriva Biologics, Inc. | -0.019M |
| Oragenics, Inc. | 0.00 |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -2.30M |
| Cash from Financing (Quarterly) | -15.90M |
| Free Cash Flow | 1.40M |
| Free Cash Flow Per Share (Quarterly) | -0.1009 |
| Free Cash Flow to Equity (Quarterly) | -0.60M |
| Free Cash Flow to Firm (Quarterly) | 7.811M |
| Free Cash Flow Yield | 0.20% |